NOV 0 9 2004

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application

Masferrer, J.L.

Serial No.:

10/692,643

Filed:

October 24, 2003

Title:

ANTIANGIOGENIC COMBINATION THERAPY FOR THE

TREATMENT OF CANCER

Group Art Unit:

1614

Examiner:

R. Cook

Confirmation No.: 8629

Docket No.:

6794F-000032/US/DVK

Client Ref.:

3167/12A/US

CERTIFICATE OF MAILING

I certify that this paper, together with any attachments thereto, is being deposited with the United States Postal Service with sufficient postage as FIRST CLASS MAIL in an envelope addressed to: Commissioner for Patents, Mail Stop Amendment, P.O. Box 1450, Alexandria, VA 22313-1450, on November 4, 2004.

Susan B. Gawlik

November 4, 2004

Commissioner for Patents Mail Stop Amendment P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

RESPONSE TO OFFICE ACTION DATED OCTOBER 4, 2004

This paper is responsive to the Office Action dated October 4, 2004 in the abovereferenced application, and is submitted within the 1 month shortened statutory period set for reply, accordingly no fee for extension of time is believed payable.

Claims 1–23 are pending in the application. By the present Office Action, Applicant is required under 35 U.S.C. §121 to elect for examination a single disclosed species of Cox-2 selective inhibitor from those recited in the claims.

Applicant elects without traverse the species wherein the Cox-2 selective inhibitor is <u>celecoxib</u>. The claims that read on the elected species are Claims 1-4, 8-13, 17-19 and 23.

Serial No. 10/692,643 6794F-000032/US/DVK (3167/12A/US) Response to Office Action dated October 4, 2004 November 4, 2004

Should any questions remain in relation to the present Office Action, the Examiner is invited to call the undersigned at the telephone number given below.

Respectfully submitted,

James C Forbes

HARNESS, DICKEY & PIERCE, P.L.C.

James C. Forbes

Agent for Applicant

Reg. No. 39,457

Tel. 847-412-6350